<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> have a 40% increased risk of <z:e sem="disease" ids="C0005684" disease_type="Neoplastic Process" abbrv="">bladder cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="50864">Thiazolidinediones</z:chebi>, especially <z:chebi fb="0" ids="8228">pioglitazone</z:chebi>, may increase the risk </plain></SENT>
<SENT sid="2" pm="."><plain>We conducted a systematic review and meta-analysis to evaluate the risk of <z:e sem="disease" ids="C0005684" disease_type="Neoplastic Process" abbrv="">bladder cancer</z:e> among adults with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> taking <z:chebi fb="0" ids="50864">thiazolidinediones</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: We searched key biomedical databases (including MEDLINE, Embase and Scopus) and sources of grey literature from inception through March 2012 for published and unpublished studies, without language restrictions </plain></SENT>
<SENT sid="4" pm="."><plain>We included randomized controlled trials (RCTs), cohort studies and case-control studies that reported incident <z:e sem="disease" ids="C0005684" disease_type="Neoplastic Process" abbrv="">bladder cancer</z:e> among people with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> who ever (v </plain></SENT>
<SENT sid="5" pm="."><plain>never) were exposed to <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> (main outcome), <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> or any thiazolidinedione </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Of the 1787 studies identified, we selected 4 RCTs, 5 cohort studies and 1 case-control study </plain></SENT>
<SENT sid="7" pm="."><plain>The total number of patients was 2 657 365, of whom 3643 had newly diagnosed <z:e sem="disease" ids="C0005684" disease_type="Neoplastic Process" abbrv="">bladder cancer</z:e>, for an overall incidence of 53.1 per 100 000 person-years </plain></SENT>
<SENT sid="8" pm="."><plain>The one RCT that reported on <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> use found no significant association with <z:e sem="disease" ids="C0005684" disease_type="Neoplastic Process" abbrv="">bladder cancer</z:e> (risk ratio [RR] 2.36, 95% confidence interval [CI] 0.91-6.13) </plain></SENT>
<SENT sid="9" pm="."><plain>The cohort studies of <z:chebi fb="0" ids="50864">thiazolidinediones</z:chebi> (pooled RR 1.15, 95% CI 1.04-1.26; I(2) = 0%) and of <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> specifically (pooled RR 1.22, 95% CI 1.07-1.39; I(2) = 0%) showed significant associations with <z:e sem="disease" ids="C0005684" disease_type="Neoplastic Process" abbrv="">bladder cancer</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>No significant association with <z:e sem="disease" ids="C0005684" disease_type="Neoplastic Process" abbrv="">bladder cancer</z:e> was observed in the two RCTs that evaluated <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> use (pooled RR 0.87, 95% CI 0.34-2.23; I(2) = 0%) </plain></SENT>
<SENT sid="11" pm="."><plain>INTERPRETATION: The limited evidence available supports the hypothesis that <z:chebi fb="0" ids="50864">thiazolidinediones</z:chebi>, particularly <z:chebi fb="0" ids="8228">pioglitazone</z:chebi>, are associated with an increased risk of <z:e sem="disease" ids="C0005684" disease_type="Neoplastic Process" abbrv="">bladder cancer</z:e> among adults with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>